This trial is evaluating whether Capivasertib will improve 1 primary outcome and 12 secondary outcomes in patients with Lymphoma, Diffuse. Measurement will happen over the course of From Cycle 1 (28-day treatment cycle) Day 1 until documented response (also until PD/Death for those who never respond) [Assessed Up to 1.6 Years].
This trial requires 272 total participants across 1 different treatment group
This trial involves a single treatment. Capivasertib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Capivasertib appears to be well tolerated in subjects with relapsed or refractory indolent non-Hodgkin's lymphomas. Given its unique mechanism of action, this agent may represent a valid therapeutic option for patients with indolent NHLs and warrants further investigation." - Anonymous Online Contributor
"1. The main cause of lymphoma is not HIV infection itself, but rather its complications. 2. The two types of lymphomas which cause the highest mortality rates are those caused by Epstein Barr Virus (EBV) and Kaposi's Sarcoma-associated herpesvirus (KSHV). 3. EBV causes all forms of B-cell lymphomas. 4. Putative viral agents include human T-lymphotropic viruses (HTLV1 and HTLV2), human parvoviruses (B19 and HCMV), and other viruses. 5. A combination of genetic predisposition and environmental factors may contribute to lymphoma development. 6." - Anonymous Online Contributor
"Survival rates vary depending upon staging and type of lymphoma, and the disease responds well to treatment. In general, survival rates for follicular lymphomas are higher than those for diffuse large B-cell lymphomas. For patients who are diagnosed early, have been treated with chemotherapy or radiotherapy, and receive maintenance therapy, 5 year overall survival is approximately 85%. However, for patients who have advanced disease and no treatment, only one quarter survive more than 5 years. There are also differences in survival between the genders. Women tend to live longer than men." - Anonymous Online Contributor
"The mean age someone with lymphoma gets the disease is 64 years old for HL and 58 years old for NHL. About 50% of patients diagnosed with NHL get the disease before 55 years old. About 32% of patients diagnosed with HL get the disease before 65 years old. Patients with high grade B cell lymphomas tended to have a higher mean age at diagnosis than patients with low grade B cell lymphomas." - Anonymous Online Contributor
"The odds of developing lymphoma increases for those who have more than 10 years-old children. However, the odds also increase among adults who have more than one first degree relative with lymphoma. Recent findings suggest that genetic predisposition may play a role in determining risk of developing lymphoma in individuals." - Anonymous Online Contributor
"Capivasertib was well tolerated, but did not improve progression-free survival compared to placebo in patients with relapsed or refractory follicular lymphoma. Overall survival data were inconclusive due to early closure of the trial. Additional studies are needed to confirm these results before capivasertib can be recommended as a treatment option. Clinicaltrials.gov identifier: NCT01797636." - Anonymous Online Contributor
"In this article we describe the different types of lymphomas encountered in the Indian population and provide guidelines for the diagnosis and management of these diseases." - Anonymous Online Contributor
"This year, the FDA approved capivasertib as a treatment for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who have received prior systemic therapy. In December 2017, Pfizer and Bristol-Myers Squibb announced they had reached a deal to acquire the global market rights to capivasertib from Pharmacia & Upjohn for up to $1 billion, with $900 million upfront and a further $900 million contingent upon successful regulatory submissions. In April 2018, Pfizer announced it would be paying $2.9 billion over two years to acquire the existing global sales and marketing rights to capivasertib from Pharmacia & Upjohn." - Anonymous Online Contributor
"Most patients with lymphoma should be evaluated with imaging studies. A CT scan is preferred over MRI as it shows more anatomically relevant data. Bone marrow aspirations are recommended to evaluate for involvement of bone marrow by lymphoma. Imaging is also used to evaluate for other masses that could mimic lymphoma. Depending on the nature of the mass, PET/CT may be helpful." - Anonymous Online Contributor
"In summary, lymphoma is a deadly disease, especially when the patient has disseminated disease. It is important that patients with a history of lymphoma are aware of their high risk of developing secondary cancers in their remaining lifetime. Patients with multiple extranodal sites of disease should be considered for more intensive surveillance and treatment regimes than those with single sites, even if the course of the disease is apparently benign." - Anonymous Online Contributor
"Capivasertib was efficacious in patients with advanced NSCLC. The drug did not cause any significant harm in terms of serious side effects. Results from a recent paper provides further evidence that capivasertib may be an effective treatment option for patients with advanced NSCLC." - Anonymous Online Contributor